Vividion Therapeutics, Inc., a biotechnology company, has secured $135 million in Series C financing. Logos Capital and Boxer Capital of Tavistock Group led the round.
Source: Press Release
Vividion Therapeutics racks up $135m Series C
Vividion Therapeutics, Inc., a biotechnology company, has secured $135 million in Series C financing.
If you do not receive this within five minutes, please try and sign in again. If the problem persists, please
email: